Evidence-Based Innovation: The Science Behind EarliPoint®

Study Locations

Join the EarliPoint® Network

Answer a few quick questions to see if you qualify for low-cost access to EarliPoint® and opportunities to join the EarliPoint® Network. Takes ~2–3 minutes.

EarliPoint® Clinical Validation Trials

EarliPoint’s recent studies, featured in The Journal of the American Medical Association (JAMA), reveal the effectiveness of quantifying moment-by-moment looking behavior as a biomarker for objectively assessing the presence or absence of autism. These studies also measure individual children’s functioning across the three core domains of autism – social disability, verbal ability, and nonverbal learning.

DATE: September 5, 2023

Eye-Tracking-Based Measurement of Social Visual Engagement Compared with Expert Clinical Diagnosis of Autism

DATE: September 5, 2023

Development and Replication of Objective Measurements of Social Visual Engagement to Aid in Early Diagnosis and Assessment of Autism

Additional Research References

  1. Jones, W. & Klin, A. (2013). Attention to eyes is present but in decline in 2–6-month-old infants later diagnosed with autism. Nature, 504, 427–431.
  2. Constantino, J., Kennon-McGill, S., Weichselbaum, C., Marrus, N., Haider, A., Glowinski, A., Gillespie, S., Klaiman, C., Klin, A., & Jones, W. (2017). Infant viewing of social scenes is under genetic control and is atypical in autism. Nature, 547, 340–344.
  3. Shultz, S., Klin, A., & Jones, W. (2018). Neonatal transitions in social behavior and their implications for autism. Trends in Cognitive Sciences, 22(5), 452–469.
  4. Rice, K., Moriuchi, J., Jones, W., & Klin, A. (2012). Parsing heterogeneity in autism spectrum disorders: visual scanning of dynamic social scenes in school-age children. Journal of the American Academy of Child and Adolescent Psychiatry, 51(3), 238–248.
  5. Shultz, S., Klin, A., & Jones, W. (2011). Inhibition of eye blinking reveals subjective perceptions of stimulus salience. Proceedings of the National Academy of Sciences of the USA, 108, 21270–21275.
  6. Klin, A., Lin, D. J., Gorrindo, P., Ramsay, G., & Jones, W. (2009). Two-year-olds with autism fail to orient towards human biological motion but attend instead to non-social, physical contingencies. Nature, 459, 257–261.
  7. Jones, W., Carr, K., & Klin, A. (2008). Absence of preferential looking to the eyes of approaching adults predicts level of social disability in 2-year-olds with autism. Archives of General Psychiatry, 65(8), 946–954.
  8. Klin, A., Jones, W., Schultz, R., Volkmar, F., & Cohen, D. (2002). Visual fixation patterns during viewing of naturalistic social situations as predictors of social competence in individuals with autism. Archives of General Psychiatry, 59, 809–816.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder